TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01044004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg/day for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 150mg/day for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg/day for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 150mg/day for 13 weeks
Study: NCT02491671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard preventive measures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard preventive measures
Study: NCT04369092

Intervention type: OTHER
Group type: OTHER
Intervention: DYMUS
Description: DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.

Intervention type: OTHER
Group type: OTHER
Intervention: DYMUS
Description: DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.

Intervention type: OTHER
Group type: OTHER
Intervention: DYMUS
Description: DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
Study: NCT02444455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
Study: NCT01398488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Patient education by health care professional compared to education via tablet PC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education by health care professional compared to education via tablet PC
Study: NCT02368249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are receiving a post-operative intravenous Ringer's lactate solution
Study: NCT04282135

Intervention type: DIAGNOSTIC_TEST
Intervention: MCC IMS
Description: Diagnosis by MCC IMS

Intervention type: DIAGNOSTIC_TEST
Intervention: MCC IMS
Description: Diagnosis by MCC IMS

Intervention type: DIAGNOSTIC_TEST
Intervention: MCC IMS
Description: Diagnosis by MCC IMS
Study: NCT02006147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Study: NCT02558010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Perioperative IV methadone to be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
Study: NCT02380833

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate
Description: To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
Study: NCT03070613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescent Lectin Application
Description: Fluorescein conjugated wisteria floribunda (a lectin).
Study: NCT04647149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approach
Description: Dietary approaches with energy restriction performed at different times of the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approach
Description: Dietary approaches with energy restriction performed at different times of the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approach
Description: Dietary approaches with energy restriction performed at different times of the day.
Study: NCT02293538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FID 114657 eye drops (10 ml)
Description: Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline control eye drops (15 ml)
Description: Saline eye drops (15 ml)
Study: NCT02380833

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate + Exercise
Description: To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic
Description: To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic + Exercise
Description: To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
Study: NCT02155283

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Passive Motion
Description: Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
Study: NCT02923453

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CNT 2000 American ginseng extract
Study: NCT02006147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Study: NCT00539539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laerdal Q-CPR /technology
Description: For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
Study: NCT02923453

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04370171

Intervention type: OTHER
Intervention: care modalities
Description: For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.

Intervention type: OTHER
Intervention: Teleconsultation either by phone or by computer consultation
Description: Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
Study: NCT02594033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
Study: NCT02293538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lenses
Description: Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
Study: NCT02697253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 and Sitagliptin
Description: Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 and Sitagliptin
Description: Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours.
Study: NCT03924726

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Micro-osteoperforation (MOP)
Description: Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Micro-osteoperforation (MOP)
Description: Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
Study: NCT02697253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours.
Study: NCT05086367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic and pursed lip breathing
Description: Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
Study: NCT03924726

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Micro-osteoperforation (MOP)
Description: Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
Study: NCT02958735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Challenge
Description: Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
Study: NCT05086367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
Study: NCT04386330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance-delivered NET
Description: One-on-one intervention delivered by a paraprofessional; 12 weekly videoconference sessions at 90 minutes.
Study: NCT04282941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen in continuous (24 hours) iv infusion and EchoG
Description: The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
Study: NCT01587651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Loading Dose
Description: 60mg given as six 10mg film coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Maintenance Dose
Description: 10mg maintenance dose, given as one 10mg film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel Maintenance Dose
Description: 10mg maintenance dose, given as one 10mg film coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor Maintenance Dose
Description: one 90mg film coated tablet
Study: NCT04282941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV bolus Ibuprofen slow (15 minutes) and EchoG
Description: The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
Study: NCT03342638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Potent immunosuppressive agent; an alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Potent immunosuppressive agent; an alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study: NCT02875613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
Study: NCT04740398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1008
Description: CBP-1008 for injection; IV infusion; Infusion for 90 minutes
Study: NCT03647618

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound-guided regional anaesthesia
Study: NCT05418998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function (EF) training
Description: EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
Study: NCT00992901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and GIP
Description: A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
Study: NCT00558701

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent stimulator
Description: Microcurrent stimulation from 15-50 microamps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon Wound Contact Dressing
Description: Silver coated nylon dressing FDA approved for use on donor sites in burn patients

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silverlon Wound Contact Dressing
Description: Silver coated nylon dressing FDA approved for use on donor sites in burn patients
Study: NCT04067167

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: WB-EMS (Sham-intervention)
Description: Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexi band resistance training
Description: Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform resistance exercises using flexi bands~* flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~* time-effort per session: \~20 min~* 2 training sessions per week
Study: NCT04614935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Plan
Description: See arm description.
Study: NCT01006187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal lidocaine
Description: 4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray
Description: medium stream spray on arm for 4-10 seconds prior to injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rubbing adjacent to the injection site
Description: rubbing adjacent to the injection site before and during injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distraction
Description: By means of self-selected reading material or video